Cervical Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017 - Product Image

Cervical Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017

  • ID: 4342714
  • Report
  • 102 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Alere Inc
  • BioMark Technologies Inc
  • Enzo Life Sciences Inc
  • GRANT Life Sciences, Inc.
  • Newcastle University
  • Precision Biologics Inc
  • MORE
Cervical Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017

Summary

The Medical Devices sector report, “Cervical Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017" provides an overview of Cervical Cancer Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Cervical Cancer Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by a team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Cervical Cancer Diagnostic Tests under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Cervical Cancer Diagnostic Tests and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment/industry
Reasons to buy

The report enables you to:
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Cervical Cancer Diagnostic Tests under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Alere Inc
  • BioMark Technologies Inc
  • Enzo Life Sciences Inc
  • GRANT Life Sciences, Inc.
  • Newcastle University
  • Precision Biologics Inc
  • MORE
1 Table of Contents
2 Introduction
2.1 Cervical Cancer Diagnostic Tests Overview
3 Products under Development
3.1 Cervical Cancer Diagnostic Tests - Pipeline Products by Stage of Development
3.2 Cervical Cancer Diagnostic Tests - Pipeline Products by Territory
3.3 Cervical Cancer Diagnostic Tests - Pipeline Products by Regulatory Path
3.4 Cervical Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date
3.5 Cervical Cancer Diagnostic Tests - Ongoing Clinical Trials
4 Cervical Cancer Diagnostic Tests - Pipeline Products under Development by Companies
4.1 Cervical Cancer Diagnostic Tests Companies - Pipeline Products by Stage of Development
4.2 Cervical Cancer Diagnostic Tests - Pipeline Products by Stage of Development
5 Cervical Cancer Diagnostic Tests Companies and Product Overview
5.1 Alere Inc Company Overview
5.1.1 Alere Inc Pipeline Products & Ongoing Clinical Trials Overview
5.2 Becton Dickinson and Co Company Overview
5.2.1 Becton Dickinson and Co Pipeline Products & Ongoing Clinical Trials Overview
5.3 Bio Techne Corp Company Overview
5.3.1 Bio Techne Corp Pipeline Products & Ongoing Clinical Trials Overview
5.4 BioAffinity Technologies, Inc. Company Overview
5.4.1 BioAffinity Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.5 BioMark Diagnostics Inc. Company Overview
5.5.1 BioMark Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.6 BioMark Technologies Inc Company Overview
5.6.1 BioMark Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
5.7 Cepheid Company Overview
5.7.1 Cepheid Pipeline Products & Ongoing Clinical Trials Overview
5.8 China Sky One Medical Inc Company Overview
5.8.1 China Sky One Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
5.9 Cytosystems Ltd Company Overview
5.9.1 Cytosystems Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.10 Enzo Life Sciences Inc Company Overview
5.10.1 Enzo Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview
5.11 Genisphere LLC Company Overview
5.11.1 Genisphere LLC Pipeline Products & Ongoing Clinical Trials Overview
5.12 Genomic Vision Company Overview
5.12.1 Genomic Vision Pipeline Products & Ongoing Clinical Trials Overview
5.13 GenomicTree Inc Company Overview
5.13.1 GenomicTree Inc Pipeline Products & Ongoing Clinical Trials Overview
5.14 Golden Valley Development, Inc. Company Overview
5.14.1 Golden Valley Development, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.15 GRANT Life Sciences, Inc. Company Overview
5.15.1 GRANT Life Sciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.16 Louisville Bioscience, Inc. Company Overview
5.16.1 Louisville Bioscience, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.17 MDNA Life Sciences Inc Company Overview
5.17.1 MDNA Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview
5.18 MDxHealth SA Company Overview
5.18.1 MDxHealth SA Pipeline Products & Ongoing Clinical Trials Overview
5.19 Milagen Inc Company Overview
5.19.1 Milagen Inc Pipeline Products & Ongoing Clinical Trials Overview
5.20 Newcastle University Company Overview
5.20.1 Newcastle University Pipeline Products & Ongoing Clinical Trials Overview
5.21 Olympia Diagnostics, Inc Company Overview
5.21.1 Olympia Diagnostics, Inc Pipeline Products & Ongoing Clinical Trials Overview
5.22 Oncgnostics GmbH Company Overview
5.22.1 Oncgnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview
5.23 ONCOVEDA Cancer Research Center Company Overview
5.23.1 ONCOVEDA Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview
5.24 Orion Genomics LLC Company Overview
5.24.1 Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview
5.25 Precision Biologics Inc Company Overview
5.25.1 Precision Biologics Inc Pipeline Products & Ongoing Clinical Trials Overview
5.26 Preciva Incorporated Company Overview
5.26.1 Preciva Incorporated Pipeline Products & Ongoing Clinical Trials Overview
5.27 Roche Diagnostics International Ltd Company Overview
5.27.1 Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.28 University of Manchester Company Overview
5.28.1 University of Manchester Pipeline Products & Ongoing Clinical Trials Overview
5.29 US Biomarkers Inc Company Overview
5.29.1 US Biomarkers Inc Pipeline Products & Ongoing Clinical Trials Overview
5.30 Vanderbilt University Company Overview
5.30.1 Vanderbilt University Pipeline Products & Ongoing Clinical Trials Overview
5.31 XEPTAGEN SpA Company Overview
5.31.1 XEPTAGEN SpA Pipeline Products & Ongoing Clinical Trials Overview
6 Cervical Cancer Diagnostic Tests - Recent Developments
6.1 Jul 25, 2017: Quest Diagnostics Reports Second Quarter 2017 Financial Results, Raises 2017 Financial Outlook
6.2 Jun 15, 2017: Oxford Immunotec Announces Favorable Claim Construction Ruling in Patent Infringement Litigation
6.3 Jun 09, 2017: R-way achievement in The 16th IFCPC Congress
6.4 Jun 06, 2017: BD Releases 2016 Sustainability Report
6.5 Jun 02, 2017: Cancer Genetics to Present at the 7th Annual LD Micro Invitational
6.6 May 17, 2017: Mel-Mont Medical announces the development of Mia by XytoTest, a self-collected cervical sample that seeks to eradicate cervical cancer
6.7 May 11, 2017: Cancer Genetics Announces 15% Revenue Increase in First Quarter of 2017 over 2016 on Strong Organic Growth While Continuing on Path to Profitability
6.8 May 10, 2017: Genomic Vision Announces Promising Preliminary Results for Its Clinical Study in Cervical Cancer Detection in the Czech Republic
6.9 May 10, 2017: MEDITE Cancer Diagnostics Announces Reorganization of Germany Operations
6.10 May 09, 2017: Genomic Vision: Financial Information at March 31, 2017
6.11 May 08, 2017: MDxHealth Trading Update: January to April 2017
6.12 May 02, 2017: BD Announces Results For 2017 Second Fiscal Quarter
6.13 Apr 28, 2017: MEDITE Cancer Diagnostics Announces Reorganization of Germany Operations
6.14 Apr 27, 2017: MEDITE Cancer Diagnostics Appoints Susan Weisman as Chief Financial Officer
6.15 Apr 23, 2017: BD Announces Appointment Of Tom Polen As President
6.16 Apr 20, 2017: Quest Diagnostics Reports First Quarter 2017 Financial Results, Raises 2017 Financial Outlook
6.17 Mar 28, 2017: BD Announces Success of Helping Build Healthy Communities Program, Launches New Effort Focused on Medication Therapy Management
6.18 Mar 23, 2017: Cancer Genetics Announces Record Revenue for Fourth Quarter and Full-Year 2016 and Provides 2017 Business Update
6.19 Mar 22, 2017: Vigilant Biosciences Announces Multiple Poster Presentations in Support of OncAlert Oral Cancer and OncAlert Labs Product Lines
6.20 Mar 21, 2017: Retractable Technologies Announces Litigation Updates
6.21 Mar 13, 2017: Cancer Genetics to Present at “A Future Without Cancer Conference” on Friday, March 17
6.22 Mar 07, 2017: MEDITE Cancer Diagnostics Appoints Eric M. Goehausen to Board of Directors
6.23 Mar 01, 2017: Genomic Vision: 2016 Annual Results
6.24 Feb 27, 2017: Bristol-Myers Squibb Expands International Immuno-Oncology Network (II-ON) With Addition of Columbia University Medical Center and Peter MacCallum Cancer Centre
6.25 Feb 23, 2017: MDxHealth Reports Financial Year 2016 Results
6.26 Feb 02, 2017: BD Announces Results For 2017 First Fiscal Quarter
6.27 Jan 26, 2017: Quest Diagnostics Reports Fourth Quarter And Full Year 2016 Financial Results; Provides Guidance For Full Year 2017
6.28 Jan 26, 2017: Quest Diagnostics Partners With Montefiore Health System to Deliver High-Value, Innovative Laboratory Services
6.29 Jan 09, 2017: MDxHealth Announces Preliminary Update on 2016 Results and Appointment of CFO
6.30 Jan 09, 2017: Genomic Vision Doubles Its Installed Base of FiberVision Platforms and Quadruples Its Sales of Products and Services in 2016
6.31 Jan 06, 2017: Cancer Genetics Announces Consolidation and Cost Reduction in Administrative and Operational Support Functions
6.32 Dec 20, 2016: Singulex Opens European Office and Advances IVD System Evaluation
6.33 Dec 16, 2016: MDxHealth Receives ISO 13485:2016 Certification for Dutch Laboratory
6.34 Dec 15, 2016: Quest Diagnostics Board of Directors Elects Stephen H. Rusckowski Chairman of the Board
6.35 Nov 11, 2016: Quest Diagnostics Raises Revenue Growth Outlook, Increases Dividend at 2016 Investor Day
6.36 Nov 10, 2016: Cancer Genetics Announces Strong Third Quarter with 68% Year over Year Revenue Growth and Highlights Path to Future Profitability
6.37 Nov 03, 2016: BD Announces Results For 2016 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2017 Guidance
6.38 Nov 02, 2016: MDxHealth Provides Third Quarter 2016 Business Update
6.39 Oct 20, 2016: Quest Diagnostics Reports Third Quarter 2016 Financial Results
6.40 Sep 22, 2016: MDxHealth Announces Upgraded Revenue Forecast
6.41 Sep 20, 2016: Early Detection of Ervical cancer: “ GynTect 2.0“- Wider Range of Application by Using a Greater Variety of Patient Samples
6.42 Aug 24, 2016: bioAffinity Awarded New Patent; Company’s Patent Portfolio Continues to Expand
6.43 Aug 18, 2016: MDxHealth Reports Second Quarter and First Half 2016 Results
6.44 Aug 09, 2016: Cancer Genetics Reports Second Quarter 2016 Financial Results and Provides Company Updates
6.45 Aug 04, 2016: BD Announces Results For 2016 Third Fiscal Quarter
7 Appendix
7.1 Methodology
7.2 About
7.3 Contact
7.4 Disclaimer

List of Tables
Table 1: Cervical Cancer Diagnostic Tests - Pipeline Products by Stage of Development
Table 2: Cervical Cancer Diagnostic Tests - Pipeline Products by Territory
Table 3: Cervical Cancer Diagnostic Tests - Pipeline Products by Regulatory Path
Table 4: Cervical Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date
Table 5: Cervical Cancer Diagnostic Tests - Ongoing Clinical Trials
Table 6: Cervical Cancer Diagnostic Tests Companies - Pipeline Products by Stage of Development
Table 7: Cervical Cancer Diagnostic Tests - Pipeline Products by Stage of Development
Table 8: Alere Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 9: NMP179 Test - Product Status
Table 10: NMP179 Test - Product Description
Table 11: Becton Dickinson and Co Pipeline Products & Ongoing Clinical Trials Overview
Table 12: BD SurePath Plus Molecular Pap Test System - Product Status
Table 13: BD SurePath Plus Molecular Pap Test System - Product Description
Table 14: Biomarker Test - Cervical Cancer - Product Status
Table 15: Biomarker Test - Cervical Cancer - Product Description
Table 16: Bio Techne Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 17: RNAscope HPV Assay - Cervical Cancer - Product Status
Table 18: RNAscope HPV Assay - Cervical Cancer - Product Description
Table 19: BioAffinity Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 20: CyPath Diagnostic Assay - Cervical Cancer - Product Status
Table 21: CyPath Diagnostic Assay - Cervical Cancer - Product Description
Table 22: BioMark Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 23: Metabolomics-based Diagnostic Assay - Cervical Cancer - Product Status
Table 24: Metabolomics-based Diagnostic Assay - Cervical Cancer - Product Description
Table 25: BioMark Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 26: Biomarker Assay - Cervical Cancer - Product Status
Table 27: Biomarker Assay - Cervical Cancer - Product Description
Table 28: Cepheid Pipeline Products & Ongoing Clinical Trials Overview
Table 29: Xpert Molecular PAP Assay - Product Status
Table 30: Xpert Molecular PAP Assay - Product Description
Table 31: China Sky One Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 32: Diagnostic Kit - Carcinoma Cervix - Product Status
Table 33: Diagnostic Kit - Carcinoma Cervix - Product Description
Table 34: Cytosystems Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 35: Laboratory-Based Diagnostic Test - Cervical Cancer - Product Status
Table 36: Laboratory-Based Diagnostic Test - Cervical Cancer - Product Description
Table 37: Enzo Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 38: Next-Generation Branched DNA Assay - Cervical Cancer - Product Status
Table 39: Next-Generation Branched DNA Assay - Cervical Cancer - Product Description
Table 40: Genisphere LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 41: miRNA Biomarker Diagnostic Test - Cervical Cancer - Product Status
Table 42: miRNA Biomarker Diagnostic Test - Cervical Cancer - Product Description
Table 43: Genomic Vision Pipeline Products & Ongoing Clinical Trials Overview
Table 44: HPV Combing Test - Product Status
Table 45: HPV Combing Test - Product Description
Table 46: Genomic Vision - Ongoing Clinical Trials Overview
Table 47: HPV Combing Test - Association Between High-risk HPV Genome Integration Detected by Molecular Combing and Cervical Lesions Severity and/or Evolution
Table 48: HPV Combing Test - Integration of Oncogenic HPV DNA in Czech Republic
Table 49: GenomicTree Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 50: EarlyTect Cervical Cancer - Product Status
Table 51: EarlyTect Cervical Cancer - Product Description
Table 52: Screening Test - Cervical Cancer - Product Status
Table 53: Screening Test - Cervical Cancer - Product Description
Table 54: Golden Valley Development, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 55: XytoTest - Product Status
Table 56: XytoTest - Product Description
Table 57: GRANT Life Sciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 58: Serum-Based Test - Cervical Cancer - Product Status
Table 59: Serum-Based Test - Cervical Cancer - Product Description
Table 60: Louisville Bioscience, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 61: Cervical Cancer Remission pT Test - Product Status
Table 62: Cervical Cancer Remission pT Test - Product Description
Table 63: MDNA Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 64: Diagnostic Test - Cervical Cancer - Product Status
Table 65: Diagnostic Test - Cervical Cancer - Product Description
Table 66: MDxHealth SA Pipeline Products & Ongoing Clinical Trials Overview
Table 67: ClinicalMDx - Cervical Cancer - Product Status
Table 68: ClinicalMDx - Cervical Cancer - Product Description
Table 69: Milagen Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 70: Immunoassay - Cervical Cancer - Product Status
Table 71: Immunoassay - Cervical Cancer - Product Description
Table 72: Newcastle University Pipeline Products & Ongoing Clinical Trials Overview
Table 73: SmartHEALTH POC System - Cervical Cancer - Product Status
Table 74: SmartHEALTH POC System - Cervical Cancer - Product Description
Table 75: Olympia Diagnostics, Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 76: Diagnostic Test - Cervical Cancer - Product Status
Table 77: Diagnostic Test - Cervical Cancer - Product Description
Table 78: Prognostic Test - Cervical Cancer - Product Status
Table 79: Prognostic Test - Cervical Cancer - Product Description
Table 80: Oncgnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview
Table 81: GynTect - Product Status
Table 82: GynTect - Product Description
Table 83: GynTect 2.0 - Product Status
Table 84: GynTect 2.0 - Product Description
Table 85: ONCOVEDA Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview
Table 86: HPV Companion Diagnostic Test - Cervical Cancer - Product Status
Table 87: HPV Companion Diagnostic Test - Cervical Cancer - Product Description
Table 88: Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 89: Diagnostic Assay - Cervical Cancer - Product Status
Table 90: Diagnostic Assay - Cervical Cancer - Product Description
Table 91: Precision Biologics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 92: Diagnostic Assay - Cervical Cancer - Product Status
Table 93: Diagnostic Assay - Cervical Cancer - Product Description
Table 94: Preciva Incorporated Pipeline Products & Ongoing Clinical Trials Overview
Table 95: mColposcope - Product Status
Table 96: mColposcope - Product Description
Table 97: Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 98: CINtec Plus Cytology Kit - Product Status
Table 99: CINtec Plus Cytology Kit - Product Description
Table 100: University of Manchester Pipeline Products & Ongoing Clinical Trials Overview
Table 101: Diagnostic Test - Cervical Cancer - Product Status
Table 102: Diagnostic Test - Cervical Cancer - Product Description
Table 103: US Biomarkers Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 104: Blood-Based Biomarker - Cervical Cancer - Product Status
Table 105: Blood-Based Biomarker - Cervical Cancer - Product Description
Table 106: Vanderbilt University Pipeline Products & Ongoing Clinical Trials Overview
Table 107: Companion Diagnostic Assay - Cervical Cancer - Product Status
Table 108: Companion Diagnostic Assay - Cervical Cancer - Product Description
Table 109: XEPTAGEN SpA Pipeline Products & Ongoing Clinical Trials Overview
Table 110: SCCA - IgM Kit - Cervical Cancer - Product Status
Table 111: SCCA - IgM Kit - Cervical Cancer - Product Description
Table 112: Glossary

List of Figures
Figure 1: Cervical Cancer Diagnostic Tests - Pipeline Products by Stage of Development
Figure 2: Cervical Cancer Diagnostic Tests - Pipeline Products by Territory
Figure 3: Cervical Cancer Diagnostic Tests - Pipeline Products by Regulatory Path
Figure 4: Cervical Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date
Figure 5: Cervical Cancer Diagnostic Tests - Ongoing Clinical Trials
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Alere Inc
  • Becton Dickinson and Co
  • Bio Techne Corp
  • BioAffinity Technologies, Inc.
  • BioMark Diagnostics Inc.
  • BioMark Technologies Inc
  • Cepheid
  • China Sky One Medical Inc
  • Cytosystems Ltd
  • Enzo Life Sciences Inc
  • Genisphere LLC
  • Genomic Vision
  • GenomicTree Inc
  • Golden Valley Development, Inc.
  • GRANT Life Sciences, Inc.
  • Louisville Bioscience, Inc.
  • MDNA Life Sciences Inc
  • MDxHealth SA
  • Milagen Inc
  • Newcastle University
  • Olympia Diagnostics, Inc
  • Oncgnostics GmbH
  • ONCOVEDA Cancer Research Center
  • Orion Genomics LLC
  • Precision Biologics Inc
  • Preciva Incorporated
  • Roche Diagnostics International Ltd
  • University of Manchester
  • US Biomarkers Inc
  • Vanderbilt University
  • XEPTAGEN SpA
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll